5 results about "Transplanted kidney" patented technology

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

Systems and methods for identifying risk of kidney graft failure in a subject are provided. An image of a graft biopsy is obtained, the image representing at least a subset of a plurality of morphological classes including a tissue compartment and inflammation class. The image is inputted into a trained model that identifies, as output, for each morphological class in at least the subset, corresponding objects in the image that fall within the morphological class. For each morphological class, corresponding digital features are generated comprising a first subset of individual feature scores obtained using the objects for the morphological class and a second subset of composite feature scores obtained by combining individual feature scores. Digital features for each morphological class are compared to a reference criterion, thus determining risk of kidney graft failure.

Provided herein are methods and compositions for treating kidney-related disease conditions and complications, such as Berger's disease, and for preventing transplant rejection. For example, the present disclosure describes a method of improving function of a transplanted kidney in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds CD40 ligand.

This invention relates to a diagnostic kit for assessing transplant rejection status, belonging to the field of biomedical technology. The invention obtains data on the relative proportions and absolute counts of various immune cell populations in peripheral blood, and measures the ultrasound hemodynamic parameters of the transplanted kidney, including the interlobar artery resistance index and the renal aortic resistance index. It then uses the formula y1 = -1.228a + 0.008b – 0.009c to determine whether acute rejection exists. In the formula, the donor kidney type is defined as variable a, with living donor kidney = 0 and deceased donor kidney = 1; the absolute value of peripheral blood CD4 is defined as a continuous variable b; the absolute value of peripheral blood CD8 is defined as a continuous variable c; and when y1 > 0.5, acute rejection is determined. This invention makes the diagnosis of the immune status of transplanted kidneys non-invasive, optimizing the kidney transplant diagnosis and treatment process.

This invention relates to the application of reagents for detecting biomarkers in the preparation of non-invasive diagnostic products for renal interstitial fibrosis and chronic progressive injury, belonging to the field of biotechnology. The biomarkers are SNX3, VPS4B, and SMO, derived from urinary extracellular vesicles, and their expression levels increase with the degree of transplanted kidney fibrosis. The urinary extracellular vesicle separation method of this invention effectively removes urinary glomerulonephrine entangled with vesicles during ultracentrifugation without affecting the structural integrity of the extracellular vesicles or the expression of the marker proteins. The biomarkers of this invention have excellent diagnostic capabilities for transplanted kidney fibrosis and also demonstrate outstanding ability in diagnosing chronic progressive injury of transplanted kidneys, predicting the risk of transplanted kidney failure, and assessing renal fibrosis in chronic kidney disease. They possess advantages such as good stability, high specificity, and high sensitivity, and are simple to operate with a short detection cycle, enabling non-invasive diagnosis or prognostic monitoring of fibrosis in both transplanted and non-transplanted kidneys.